Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Ecopipam in Tourette's Disorder
NCT06021522Phase 3Active, not recruiting
- Sponsor
- Emalex Biosciences
- Start
- Aug 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of ecopipam in Tourette syndrome (TS), sponsored by Emalex Biosciences. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at Month 24. Started Aug 2023; status: active, not recruiting.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT06021522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021522.